AGILENT TECHNOLOGIES, INC. (A)
Agilent Receives FDA Approval for Expanded Use of PD-L1 IHC 22C3 pharmDx on Dako Omnis in Esophageal Squamous Cell Carcinoma, Triple-Negative Breast Cancer, Cervical Cancer, and Gastric or Gastroesophageal Junction Adenocarcinoma
📈 **POSITIVE** • Medium confidence analysis (76%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business